Data Science Funding Announcements & Notices

Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.

Title FOA Organization Release Date Expire Date Purpose
Single Source: Human Tumor Atlas Network Data Coordinating Center (HTAN-DCC; U24 Clinical Trial Not Allowed) RFA-CA-23-041 NCI Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate sharing of complex single-cell level data with the cancer research community. The Human… More
Human Tumor Atlas (HTA) Research Centers (U01 Clinical Trial Not Allowed) RFA-CA-23-039 NCI Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for Human Tumor Atlas (HTA) Research Centers, one of the three scientific components of… More
Pre-Cancer Atlas (PCA) Research Centers (U01 Clinical Trial Not Allowed) RFA-CA-23-040 NCI The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for Precancer Atlas (PCA) Research Centers, one of the three scientific components of the Human Tumor Atlas Network… More
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed) RFA-CA-22-057 NCI Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from… More
Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional) RFA-CA-23-033 NCI The purpose of this Funding Opportunity Announcement (FOA) is to support Implementation Science for Cancer Control in People Living with HIV (PLWH) in Low- and Middle-Income Countries (LMICs) to… More
The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional) PAR-21-348 NCI The role of EBV infection on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection and AIDS will increase our understanding through mechanistic,… More
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed) RFA-CA-22-056 NCI Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from… More
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed) PAR-21-166 NCI The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in… More
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) PAR-21-033 NCI The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-… More
Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers NOT-CA-21-028 NCI The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the… More
Vote below about this page’s helpfulness.
CAPTCHA
Image CAPTCHA

Enter the characters shown in the image.